RxDoctor Payments Data

Susan Lamonica, APRN

Psychiatric/Mental Health · Effingham, ILNPI 1104568369

Payments from drug & device makers

$3,317in general payments, 2019–2025

Across 147 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$838
  • Alkermes, Inc.$651
  • Neurocrine Biosciences, Inc.$354
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$340
  • Axsome Therapeutics, Inc.$215
  • Otsuka America Pharmaceutical, Inc.$212
  • plus $707 from 11 others

What the payments were for

  • Food & beverage$3,317100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,317 in reported general payments places this provider in the 85th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$8,787
Medicare patients
18
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$148,000
VraylarCariprazine Hcl40$59,176
Invega SustennaPaliperidone Palmitate13$46,542
AristadaAripiprazole Lauroxil13$41,868
RexultiBrexpiprazole15$25,078
AuvelityDextromethorphan Hbr/Bupropion11$11,854
Lurasidone Hcl49$8,253
Clozapine37$4,651
Aripiprazole63$3,639
Buspirone Hcl114$1,942
Quetiapine Fumarate62$1,106
Haloperidol27$972
Trazodone Hcl58$942
Duloxetine Hcl47$725
Fluoxetine Hcl38$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$354$148,00019 claims
AbbVieVraylar$838$59,17640 claims
Johnson & JohnsonInvega Sustenna$119$46,54213 claims
Alkermes, Inc.Aristada$651$41,86813 claims
Otsuka America Pharmaceutical, Inc.Rexulti$212$25,07815 claims
Axsome Therapeutics, Inc.Auvelity$215$11,85411 claims
Lilly USA, LLCOlanzapine$21$19711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Effingham

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →